Sharemaestro company-news research for GlaxoSmithKline PLC ADR (GSK), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NYSE United States Provisional evidence

Company news sentiment

GSK news sentiment

GlaxoSmithKline PLC ADR

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research Options activity RSS feed
30-day score54Neutral is 50
Early balanced news score 34/100 evidence confidence 100% direct company focus 12 current stories across 9 publishers
Latest weekly closeUSD 52.96week of 7 Aug 2026
Main news subjectMarket update77/100 share of current news
News data statusHealthy2 duplicate stories removed

Current company news

Early balanced news score

12 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone61/100 Reliability-adjusted score54/100

Freshness, source quality and evidence depth temper uncertain readings toward 50; confidence remains a separate reliability measure.

Latest source headline Splitting the MMR vaccine? Experts warn it could take a decade seekingalpha.com · 13 Aug 2026 09:16

What supports the score

Direct evidence

12 current stories are mapped specifically to GSK.

Source breadth

The read spans 9 publishers rather than depending on one outlet.

What limits the score

Too little evidence

The stories agree, but freshness-weighted evidence is only 0.419.

Confidence

Evidence confidence is 34/100, below the threshold for a firm classification.

54/100
News scoreEarly balanced news score
34/100
Confidencethin evidence
100%/100
Company news12 company stories
90/100
Story agreement10/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
15 Jul: 2 stories19 Jul: 1 stories22 Jul: 1 stories23 Jul: 1 stories28 Jul: 1 stories31 Jul: 1 stories03 Aug: 1 stories07 Aug: 1 stories10 Aug: 1 stories12 Aug: 1 stories13 Aug: 1 stories 15 Jul: tone 50, 2 stories19 Jul: tone 50, 1 stories22 Jul: tone 50, 1 stories23 Jul: tone 50, 1 stories28 Jul: tone 50, 1 stories31 Jul: tone 50, 1 stories03 Aug: tone 50, 1 stories07 Aug: tone 66, 1 stories10 Aug: tone 46, 1 stories12 Aug: tone 48, 1 stories13 Aug: tone 69, 1 stories 95505
15 Jul30 Jul13 Aug
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence8
0.419 after freshness weighting
Source breadth100
9 independent publishers
Company relevance100
share tied directly to this company
Freshness72
recency-weighted evidence
Agreement90
how closely stories agree
Publisher mix58
less reliance on one publisher

Price and news history

News score and weekly price over 26 weeks

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Feb 2026: close 57.99, indexed 100.020 Feb 2026: close 59.05, indexed 101.827 Feb 2026: close 58.66, indexed 101.206 Mar 2026: close 54.08, indexed 93.313 Mar 2026: close 52.97, indexed 91.320 Mar 2026: close 51.43, indexed 88.727 Mar 2026: close 53.41, indexed 92.103 Apr 2026: close 56.24, indexed 97.010 Apr 2026: close 57.75, indexed 99.617 Apr 2026: close 57.89, indexed 99.824 Apr 2026: close 54.01, indexed 93.101 May 2026: close 51.2, indexed 88.308 May 2026: close 50.01, indexed 86.215 May 2026: close 49.67, indexed 85.722 May 2026: close 51.38, indexed 88.629 May 2026: close 50.54, indexed 87.205 Jun 2026: close 51.52, indexed 88.812 Jun 2026: close 53.04, indexed 91.519 Jun 2026: close 50.67, indexed 87.426 Jun 2026: close 52.5, indexed 90.503 Jul 2026: close 53.66, indexed 92.510 Jul 2026: close 52.78, indexed 91.017 Jul 2026: close 51.76, indexed 89.324 Jul 2026: close 51.35, indexed 88.631 Jul 2026: close 51.69, indexed 89.107 Aug 2026: close 52.96, indexed 91.3 26 Jun 2026: news score 50, close 52.5, 3 stories5003 Jul 2026: news score 50, close 53.66, 4 stories5010 Jul 2026: news score 50, close 52.78, 8 stories5017 Jul 2026: news score 50, close 51.76, 12 stories5024 Jul 2026: news score 50, close 51.35, 13 stories5031 Jul 2026: news score 50, close 51.69, 13 stories5007 Aug 2026: news score 53, close 52.96, 13 stories53
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
26-week price-8.7%latest close 52.96
News score change+3first to latest comparable week
One-week response+2.5%Price confirming higher
Fair-value position+31.6%Materially above fair value
WeekNews scoreCloseWeekly move
07 Aug 202653USD 52.96+2.5%
31 Jul 202650USD 51.69+0.7%
24 Jul 202650USD 51.35-0.8%
17 Jul 202650USD 51.76-1.9%
10 Jul 202650USD 52.78-1.6%
03 Jul 202650USD 53.66+2.2%
26 Jun 202650USD 52.5+3.6%
Provisional evidence

News subjects

What is shaping the score

Market update
Market update486 stories · 50%
Deals and strategy463 stories · 25%
Earnings652 stories · 17%
Regulatory and legal691 stories · 8%

Source mix

Where the evidence comes from

58/100 independence
seekingalpha.com652 stories · 17%
Stock Titan502 stories · 17%
Seeking Alpha502 stories · 17%
Reuters661 stories · 8%
finance.yahoo.com461 stories · 8%
Benzinga501 stories · 8%
TradingView501 stories · 8%

Recurring subjects

Subjects appearing most often

Current evidence
Split2Regulation2Healthcare2HEALTHCARE2Vaccines1SPLIT1REGULATION1Pharma1PHARMA1Fda Approval1

Earlier readings

How the score has changed

21 comparable readings · 52 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move+050 to 50 · Broadly stable
Observed range50–5350 is the neutral baseline
Evidence depth12stories at latest stored reading · +11
Confidence31/100Provisional · +2
22 Jun50 neutral13 Aug 15:56
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
13 Aug 15:5650+031/100 (+1)12 (0)Provisional
12 Aug 23:5950-130/100 (+1)12 (+1)Provisional
10 Aug 23:5951-229/100 (-2)11 (-2)Provisional
07 Aug 23:5953+331/100 (+8)13 (-1)Provisional
03 Aug 23:5950+023/100 (-2)14 (+1)Provisional
31 Jul 23:5950+025/100 (0)13 (0)Provisional
28 Jul 23:5950+025/100 (-1)13 (0)Provisional
23 Jul 23:5950+026/100 (+1)13 (0)Provisional

Source headlines

The news behind the score

Showing 1-12 of 12

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#169Tone
seekingalpha.comDirect company coverage

Splitting the MMR vaccine? Experts warn it could take a decade

[Doctor with vial of the doses vaccine for MMR Measless, Mumps and Rubella diseases. Medicine and health care concept] angelp/iStock via Getty Images President Donald Trump's executive order aimed at splitting ​the combined measles, mumps and rubella (MMR) vaccine faces a major hurdle – none of the diseases' individual shots are currently licensed in the U.S. Only Merck (MRK [https://seekingalpha.com/symbol/MRK]) and GSK (GSK [https://seekingalpha.com/symbol/GSK]) are licensed to make combined MMR shots for U.S. patients. Merck stopped manufacturing individual vaccines for these diseases nearl

Fda ApprovalRegulationSplitVaccines
Published
13 Aug 2026 09:16
News subject
Regulatory and legal
Why this score
Operating growth
How it is used
Direct company coverage
Weighted influence
High · 48.3% · 0.3d old
Duplicates
1 consolidated
#248Tone
seekingalpha.comDirect company coverage

U.K. regulator reaffirms safety of childhood vaccination

[Syringe drawing liquid medication from medical vial] zhikun sun/iStock via Getty Images Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed the safety of pediatric vaccination, noting it remains one of the safest and most effective ways to fight many severe infectious diseases. Issuing an executive order to reduce the number of childhood vaccines administered in the U.S. and split the measles, mumps, and rubella vaccination into three separate shots on Monday, Trump suggested a link between vaccin

HEALTHCAREHealthcareREGULATIONRegulationSPLITSplit
Published
12 Aug 2026 13:13
News subject
Market update
Why this score
Negative financial language
How it is used
Direct company coverage
Weighted influence
Medium · 11.5% · 1.1d old
Duplicates
2 consolidated
#346Tone
finance.yahoo.comDirect company coverage

Trump Plans to Sign Order on Splitting Up Combined Measles Shot

(Bloomberg) -- President Donald Trump is expected to sign an executive order Monday that would recommend breaking up the combined measles, mumps and rubella vaccine into three separate shots, according to a person familiar with the matter. Most Read from Bloomberg China Unleashes $28 Trillion Capital Markets to Challenge US in AI Stocks Wobble on Hormuz Standoff as Nvidia Sinks: Markets Wrap Iran Shakes Up Security Team After Saying Oman Deal 'Very Close' Trump Amps Up Pressure on Billionaire Sargeant to Exit Venezuela GameStop's Ryan Cohen Weighs Pulling $56 Billion EBay Offer The order also

AUTISMAutismHEALTHCAREHealthcarePHARMAPharma
Published
10 Aug 2026 18:11
News subject
Deals and strategy
Why this score
Negative financial language
How it is used
Direct company coverage
Weighted influence
Medium · 17% · 2.9d old
Duplicates
2 consolidated
#466Tone
ReutersDirect company coverageScored from headlineSource lookup

GSK India first-quarter profit rises on steady vaccine demand

Published
07 Aug 2026 00:38
News subject
Earnings
Why this score
Operating growth
How it is used
Direct company coverage
Weighted influence
Medium · 19.2% · 6.6d old
Duplicates
1 consolidated
#550Tone
Stock TitanDirect company coverageScored from headlineSource lookup

GSK plc (NYSE: GSK) executive trades 38,000 shares on London market

Published
03 Aug 2026 07:23
News subject
Market update
Why this score
No clear positive or negative phrase
How it is used
Direct company coverage
Weighted influence
Low · 0.3% · 10.4d old
Duplicates
1 consolidated
#650Tone
BenzingaDirect company coverageScored from headlineSource lookup

Why Is GSK Stock Gaining Tuesday? - GSK (NYSE:GSK)

Published
31 Jul 2026 13:15
News subject
Market update
Why this score
No clear positive or negative phrase
How it is used
Direct company coverage
Weighted influence
Low · 0.1% · 13.1d old
Duplicates
1 consolidated
#850Tone
Seeking AlphaDirect company coverageScored from headlineSource lookup

GSK wins FDA nod for Jideytro lung cancer drug (GSK:NYSE)

Published
23 Jul 2026 13:28
News subject
Market update
Why this score
No clear positive or negative phrase
How it is used
Direct company coverage
Weighted influence
Low · <0.1% · 21.1d old
Duplicates
1 consolidated
#1050Tone
Seeking AlphaDirect company coverageScored from headlineSource lookup

Trevi climbs as GSK drops chronic cough therapy (TRVI:NASDAQ)

Published
19 Jul 2026 17:54
News subject
Market update
Why this score
No clear positive or negative phrase
How it is used
Direct company coverage
Weighted influence
Low · <0.1% · 24.9d old
Duplicates
1 consolidated

Earlier company news

GSK news archive

Showing 1-10 of 10 stored headlines

Stored newest first for historical research. These older headlines are retained for reference and do not contribute to the current sentiment gauge above. Where an early legacy import did not retain its canonical URL, the headline links to an exact publisher-aware source lookup instead of inventing an article address.

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context